-
U.S. FDA Approves Cyltezo® (adalimumab-adbm) as First Interchangeable Biosimilar with Humira®
16 Oct 2021 01:35 GMT
… Drug Administration (FDA) in August 2017 for the treatment … Information , including Medication Guide .
IMPORTANT … other potential pharmacological interactions. MALIGNANCY … develop. Hematological Reactions Rare reports of pancytopenia, including aplastic anemia …
-
EU Panel Likes Two Cancer Drugs, Drops One
15 Oct 2021 18:21 GMT
… two new cancer drugs have been recommended … Drug Administration (FDA) in April 2021.
In the randomized, phase 3 ASCENT trial … , neutropenia, fatigue, alopecia, anemia, vomiting, constipation, decreased appetite … is indicated for treatment of advanced NSCLC …
-
Chiesi Global Rare Diseases Announces Approval of FERRIPROX® (deferiprone) in Canada for the Treatment of Iron Overload in Sickle Cell Disease
15 Oct 2021 12:46 GMT
… patients with Diamond Blackfan anemia.
Important Safety Information … including boxed WARNING and Medication Guide.
About Chiesi … on research and development of treatments for rare and … international research-focused pharmaceuticals and healthcare group …
-
Eli Lilly's Verzenio in combo with endocrine therapy gets US FDA approval for certain people with HR+ HER2─ high risk early breast cancer
14 Oct 2021 06:27 GMT
The US Food and Drug Administration (FDA) has approved Eli … inhibitor), for the adjuvant treatment of adult patients with … of the Verzenio clinical development programme have demonstrated a … of manufacturing within the pharmaceutical industry, and Lilly is …
-
FDA Approves First-Line Pembrolizumab Plus Chemo for Cervical Cancer
13 Oct 2021 23:22 GMT
The US Food and Drug Administration (FDA) has approved the checkpoint inhibitor … " for cervical cancer.
The trial included 617 patients with persistent … group, included peripheral neuropathy, alopecia, anemia, fatigue, nausea, neutropenia, diarrhea, and …
-
FDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
13 Oct 2021 15:30 GMT
… .S. Food and Drug Administration (FDA) has approved Eli … , neutrophil count decreased, anemia, lymphocyte count decreased, … starting treatment cycles is recommended for patients who develop … However, as with any pharmaceutical product, there are substantial …
-
$14.4+ Billion Erythropoietin Drugs Market Outlook, 2021-2028 | Increasing Level of Awareness About the Benefits of EPO Therapeutics - ResearchAndMarkets.com
13 Oct 2021 10:09 GMT
… cancer, HIV and ESRD treatment, favorable reimbursements, and increase … rates for EPO drugs particularly in developing regions, which boosts … HIV, Kidney Disease and Anemia
3.4.1.2. … KEYWORD:
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets …
-
Sickle Cell Anemia Therapeutics Market 2021 Report Overview and Scope, Industry snapshot, Leading Companies and Opportunity Analysis by 2030 | Says Kenneth Research
13 Oct 2021 04:54 GMT
… which are under development for treating this disease, such … cell transplantation, and other medications such as antimetabolites, … the treatment of sickle cell anemia, owing to the drug… Lilly and Company, HemaQuest Pharmaceuticals, Emmaus Medical, Merck …
-
Anemia And Other Blood Disorder Drugs Global Market To Grow At Rate Of 12% Through 2025
11 Oct 2021 09:33 GMT
… to develop and commercialize a specific kind of drug by … for the treatment of anemia.
Global Anemia And Other Blood Disorder Drugs Market … Anemia And Other Blood Disorder Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug …
-
BeiGene Announces BRUKINSA (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia
10 Oct 2021 23:20 GMT
… initial treatment, virtually all will develop progressive … ;hematoma, rash, bruising, anemia, musculoskeletal pain, diarrhea, … selectivity. With differentiated pharmacokinetics compared to other … antiplatelet or anticoagulant medications may further increase …
About
© 1995-2021